HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA still plugging away on sunscreen rule

This article was originally published in The Rose Sheet

Executive Summary

FDA anticipates publishing its long-awaited final sunscreen monograph in the next several months, according to an agency spokeswoman. "FDA is working on the final rule for the testing and labeling of over-the-counter (OTC) sunscreens to address protection against UVB and UVA radiation," she wrote in an e-mail to "The Rose Sheet." In Department of Health and Human Services' semi-annual regulatory agenda published in April, FDA estimated it would issue the final monograph in October (1"The Rose Sheet" May 3, 2010). The monograph has been consistently delayed since the final rule first emerged in 1999, suspended in "regulatory limbo," according to the Environmental Working Group, one activist organization anxious for its release (2"The Rose Sheet" Oct. 4, 2010). FDA has been working its way through 3,000 public comments since the draft final rule was issued in 2007

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel